CRISPR Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
CRISPR Therapeutics (Nasdaq: CRSP) said members of its senior management will present at the 44th Annual J.P.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
CRISPR Therapeutics (Nasdaq: CRSP) said members of its senior management will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026 at 8:15 a.m. PT in San Francisco.
A live webcast will be available on the company’s Events & Presentations page at https://crisprtx.gcs-web.com/events, and a replay will be archived on the company website for 14 days following the presentation.
Details
News Market Reaction – CRSP
On Jan 5, the day this news came out, CRSP closed 2.57% above the previous close.
Data tracked by StockTitan Argus for the Jan 5 session.
Key Figures
- Conference edition
- 44th Annual
- J.P. Morgan Healthcare Conference
- Presentation date
- January 12, 2026
- J.P. Morgan Healthcare Conference slot
- Presentation time
- 8:15 a.m. PT
- Scheduled conference presentation
- Webcast replay period
- 14 days
- Replay available on company website
Historical Context
-
Zugo-cel efficacy and safety data across autoimmune and B-cell cancers.
-
Q3 2025 net loss and high operating expenses despite ongoing programs.
-
Strong CTX460 AATD preclinical results using SyNTase platform.
-
Monash Boston Hub launch highlighting collaborations including CRSP.
-
Announcement of upcoming SyNTase AATD data presentation at ESGCT 2025.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ZUG, Switzerland and BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 8:15 a.m. PT in San Francisco.
A live webcast of the presentation will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events. A replay of the webcast will be archived on the Company's website for 14 days following the presentation.
About CRISPR Therapeutics
Founded over a decade ago, CRISPR Therapeutics is a leading gene editing company focused on developing transformative medicines for serious diseases. The Company has evolved from a pioneering research-stage organization into an industry leader, marking a historic milestone with the approval of CASGEVY® (exagamglogene autotemcel [exa-cel]), the world’s first CRISPR-based therapy, approved for eligible patients with sickle cell disease and transfusion-dependent beta thalassemia. CRISPR Therapeutics is advancing a broad and diversified pipeline across hemoglobinopathies, oncology, regenerative medicine, cardiovascular and autoimmune, and rare diseases. The Company continues to expand its leadership in gene editing through the development of SyNTase™ editing, a novel and proprietary gene-editing platform designed to enable precise, efficient, and scalable gene correction. To accelerate and expand its impact, CRISPR Therapeutics has established strategic collaborations with leading biopharmaceutical partners, including Vertex Pharmaceuticals. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Boston, Massachusetts and San Francisco, California. To learn more, visit www.crisprtx.com.
CRISPR THERAPEUTICS® standard character mark and design logo and SyNTase™ are trademarks and registered trademarks of CRISPR Therapeutics AG. CASGEVY® and the CASGEVY logo are registered trademarks of Vertex Pharmaceuticals Incorporated. All other trademarks and registered trademarks are the property of their respective owners.
Investor Contact:
+1-617-307-7503
ir@crisprtx.com
Media Contact:
+1-617-315-4493
media@crisprtx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.